Guinness Asset Management LTD Has $251.22 Million Holdings in Johnson & Johnson $JNJ

Guinness Asset Management LTD lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,383,195 shares of the company’s stock after purchasing an additional 5,994 shares during the quarter. Johnson & Johnson comprises 4.0% of Guinness Asset Management LTD’s investment portfolio, making the stock its 9th biggest holding. Guinness Asset Management LTD owned approximately 0.06% of Johnson & Johnson worth $251,216,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Modus Advisors LLC purchased a new position in Johnson & Johnson during the third quarter valued at $281,000. Prasad Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at about $229,000. Bond & Devick Financial Network Inc. boosted its stake in Johnson & Johnson by 1.3% during the third quarter. Bond & Devick Financial Network Inc. now owns 6,579 shares of the company’s stock worth $1,220,000 after acquiring an additional 82 shares in the last quarter. Waterloo Capital L.P. grew its holdings in Johnson & Johnson by 8.7% in the third quarter. Waterloo Capital L.P. now owns 22,470 shares of the company’s stock worth $4,166,000 after purchasing an additional 1,803 shares during the period. Finally, Black Diamond Financial LLC increased its stake in shares of Johnson & Johnson by 26.9% during the third quarter. Black Diamond Financial LLC now owns 2,806 shares of the company’s stock valued at $520,000 after purchasing an additional 594 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $240.30 on Friday. The company’s 50 day moving average is $213.54 and its 200 day moving average is $193.86. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The company has a market cap of $578.95 billion, a price-to-earnings ratio of 21.75, a PEG ratio of 2.31 and a beta of 0.35. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $240.94.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, meeting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. During the same period in the previous year, the business earned $2.04 earnings per share. Johnson & Johnson’s quarterly revenue was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reached new all‑time highs and technical indicators show strong buy interest, supporting momentum buyers and ETF inflows. Johnson & Johnson Is a Resilient Blue‑Chip Stock and It Just Hit New All‑Time Highs
• Positive Sentiment: RBC raised its price target to $255 and reiterated an Outperform, saying JNJ is positioned to manage legal overhang — a catalyst for investors focused on downside risk. RBC Sees Johnson & Johnson (JNJ) Well Positioned to Manage Legal Overhang
• Positive Sentiment: Regulatory approvals deepening JNJ’s oncology and medtech footprint bolster longer‑term growth expectations for the pipeline and portfolio. Johnson & Johnson Deepens Oncology And MedTech Footprint With New Approvals
• Positive Sentiment: Recent analyst upgrades drove short‑term buying (reports note JNJ trading up on upgrades), helping push the share price higher. Johnson & Johnson (NYSE:JNJ) Trading Up 1% on Analyst Upgrade
• Neutral Sentiment: Zacks and other market commentaries note elevated investor attention — useful context but not a direct catalyst beyond increasing volatility and flows. Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Analyst commentary (Globe & Mail) provides sector context and mixed views — some analysts remain bullish while others flag valuation concerns, creating a split consensus. Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Johnson & Johnson (JNJ)
• Neutral Sentiment: Commentary questioning whether current pricing fully reflects JNJ’s refocused healthcare portfolio is worth watching for longer‑term positioning but isn’t an immediate sell signal. Is Johnson & Johnson (JNJ) Pricing Reflect Recent Healthcare Portfolio Focus?

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 16th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Raymond James Financial lifted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Morgan Stanley set a $262.00 price objective on shares of Johnson & Johnson and gave the company an “overweight” rating in a research report on Wednesday, January 28th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $233.73.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.